Nicox and Kowa sign €191.5 million pact for glaucoma drug Following the licensing agreement for NCX470, Nicox’s stock rose by 60.6% in market trading.

Nicox has broadened its partnership with Japan-based Kowa Company in a licensing deal worth up to €191.5 million ($224.7 million). The news saw Nicox’s stock rise by 60.6% in market trading.

#news #BiotechDeals #Glaucoma #PharmaMarket #DrugDevelopment #ClinicalTrials #FDA #Nicox #Kowa #NCX470

Nicox and Kowa sign €191.5 million pact for glaucoma drug Following the licensing agreement for NCX470, Nicox’s stock rose by 60.6% in market trading.

Nicox has broadened its partnership with Japan-based Kowa Company in a licensing deal worth up to €191.5 million ($224.7 million). The news saw Nicox’s stock rise by 60.6% in market trading.

#news #BiotechDeals #Glaucoma #PharmaMarket #DrugDevelopment #ClinicalTrials #FDA #Nicox #Kowa #NCX470